CBD User's Guide Project CBD On March 13, 2018 (Updated on March 25, 2019) https://www.projectcbd.org/how-to/cbd-users-guide Project CBD has created a beginner’s guide for cannabidiol & cannabis therapeutics to address key questions of CBD users. A Beginner’s Guide to CBD & Cannabis Therapeutics In 2009, a handful of CBD-rich cannabis strains were discovered serendipitously in Northern California, America’s cannabis breadbasket, where certified patients could access medical marijuana legally. Thus began a great laboratory experiment in democracy involving CBD-rich cannabis therapeutics. The advent of whole plant CBD-rich oil as a grassroots therapeutic option has changed the national conversation about cannabis. It’s no longer a question of whether [...]
Lire la suiteCBD & Cannabis Dosage Guide Martin A. Lee On May 16, 2018 (Updated on April 1, 2019) https://www.projectcbd.org/how-to/cbd-dosage-guide High dose? Low dose? CBD? THC? Optimizing one's therapeutic use of cannabis may take some experimentation. It can be relatively easy to experience medical benefits from cannabis. A puff or two of tetrahydrocannabinol (THC)-rich flower can do the trick for a lot of people. Smoking marijuana, however, is not the be-all and end-all of cannabis therapeutics. There are many ways to experience the medical benefits of cannabis, and some of them are even non-intoxicating. In recent years, the advent of potent cannabis oil concentrates, non-intoxicating cannabidiol (CBD) products, [...]
Lire la suiteCBD & the Psychedelic Receptor Lex Pelger On March 11, 2018 (Updated on April 16, 2019) https://www.projectcbd.org/science/cbd-psychedelic-receptor CBD and LSD bind to the same serotonin receptor, which mediates psychedelic altered states. But cannabidiol has anti-psychotic properties and doesn't cause hallucinations. In a shorthand that drives scientists mad, serotonin is often called ‘the neurotransmitter of happiness.’ This tag is especially troublesome as more and more flaws become apparent in the ‘serotonin hypothesis’ of depression – the idea that depression is caused by a serotonin deficit, which a pill (a serotonin reuptake inhibitor) could correct.1 Serotonin is a complex molecule in the brain and the [...]
Lire la suitePsychedelics & Cannabis Therapeutics Martin A. Lee April 17, 2019 https://www.projectcbd.org/culture/psychedelics-cannabis-therapeutics High doses of THC are hallucinogenic, and microdosing LSD is a lot like CBD. These mighty molecules can relieve human suffering and they act through the endocannabinoid system. Although it may not be obvious during these Trump-rattled times, we’re in the midst of a psychedelic revival. There is more interest than ever before in experimenting with LSD, magic mushrooms, ayahuasca, ketamine, and other psychedelic drugs. This renaissance is happening without all the fanfare of the day-glo Sixties, when lysergic acid diethylamide (LSD) escaped from the laboratory and assumed the lead role in an improbable [...]
Lire la suiteCannabinoids in the treatment of epilepsy – an updated review Marcin Kopka Journal of Epileptology, 2019, 27, Doi : 10.2478/joepi-2019-0004 SUMMARY Introduction : It is estimated that 30% of people with epilepsy continue to have seizures despite treatment. The approval of many new antiseizure drugs during the past two decades has not substantially reduced the proportion of patients with medically refractory disease. Patients need new treatments. Many families choose to try alternative therapy options. An abundance of preclinical evidence and anecdotal human data support the use of cannabinoids in the treatment of epilepsy. Aim : The present review paper aims to present the current state of [...]
Lire la suitePrenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone Roberto Frau, Vivien Miczán, Francesco Traccis, Sonia Aroni, Csaba I. Pongor, Pierluigi Saba, Valeria Serra, Claudia Sagheddu, Silvia Fanni, Mauro Congiu, Paola Devoto, Joseph F. Cheer, István Katona and Miriam Melis Nature Neuroscience, December 2019, VOL 22, 1975–1985 www.nature.com/natureneuroscience1975 Content courtesy of Springer Nature, terms of use apply. Rights reserved Doi : 10.1038/s41593-019-0512-2 The increased legal availability of cannabis has led to a common misconception that it is a safe natural remedy for, among others, pregnancy-related ailments such as morning sickness. Emerging clinical evidence, however, indicates that prenatal cannabis exposure (PCE) predisposes offspring to various neuropsychiatric [...]
Lire la suiteCannabis Use in Adolescence : A Review of Neuroimaging Findings Yann Chye, Erynn Christensen & Murat Yücel Journal of Dual Diagnosis, 2019 Doi : 10.1080/15504263.2019.1636171 ABSTRACT Objective : Shifting policies and widespread acceptance of cannabis for medical and/or recreational purposes have fueled worries of increased cannabis initiation and use in adolescents. In particular, the adolescent period is thought to be associated with an increased susceptibility to the potential harms of repeated cannabis use, due to being a critical period for neuromaturational events in the brain. This review investigates the neuroimaging evidence of brain harms attributable to adolescent cannabis use. Methods : PubMed and Scopus searches were [...]
Lire la suiteLa FDA accélère la recherche sur la psilocybine pour les troubles dépressifs majeurs Aurélien Bernard Newsweed, 28 novembre 2019 https://www.newsweed.fr/fda-accelere-recherche-psilocybine-depression/ La Food and Drug Administration (FDA) a catégorisé les champignons hallucinogènes en tant que « thérapie révolutionnaire » pour les troubles dépressifs majeurs (MDD), une démarche qui accélérera la recherche de nouveaux médicaments à partir de psilocybine. Cette classification a été créée en 2012 pour encadrer les recherches et le développement produit de médicaments à partir de susbtances ayant un potentiel fort par rapport aux options existantes et pour des patients atteints de maladie grave ou qui met leur vie en danger. La première recherche [...]
Lire la suiteAssociations of Parental Marijuana Use With Offspring Marijuana, Tobacco, and Alcohol Use and Opioid Misuse Bertha K. Madras, Beth Han, Wilson M. Compton, Christopher M. Jones, Elizabeth I. Lopez, Elinore F. McCance-Katz JAMA Network Open, 2019, 2, (11), e1916015. doi : 10.1001/jamanetworkopen.2019.16015 Abstract IMPORTANCE : Marijuana use is increasing among adults and often co-occurs with other substance use; therefore, it is important to examine whether parental marijuana use is associated with elevated risk of substance use among offspring living in the same household. OBJECTIVE : To examine associations of parental marijuana use with offspring marijuana, tobacco, and alcohol use and opioid misuse. DESIGN, SETTING, AND PARTICIPANTS : [...]
Lire la suiteEndocannabinoid-mediated synaptic plasticity and substance use disorders E. Fernandez-Espejo, L. Nunez-Dominguez Neurologia, 2019 Copyright © 2019 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved. doi : 10.1016/j.nrl.2018.12.004 Abstract Drugs impact brain reward circuits, causing dependence and addiction, in a condition currently described as substance use disorders. Mechanisms of synaptic plasticity in these circuits are crucial in the development of addictive behaviour, and endocannabinoids, particularly anandamide and 2-arachidonyl-glycerol, participate in normal neuroplasticity. Substance use disorders are known to be associated with disruption of endocannabinoid-mediated synaptic plasticity, among other phenomena. Endocannabinoids mediate neuroplasticity in the short and the long term. In the short term, [...]
Lire la suite